Purpose: Glioblastoma is one of the most lethal cancers in humans, and with existing therapy, survival remains at 14.6 months. Current barriers to successful treatment include their infiltrative behavior, extensive tumor heterogeneity, and the presence of a stem-like population of cells, termed brain tumor-initiating cells (BTIC) that confer resistance to conventional therapies.
Introduction
Grade IV glioma and glioblastoma are the most lethal and aggressive forms of brain tumors in adults. Despite treatment advances combining maximal surgical resection with radiotherapy and concurrent and adjuvant chemotherapy (temozolomide), patient prognosis remains disappointing and survival is limited to 14.6 months with few cases of long-term survivors (1) . Current barriers to successful treatment include their complex tumor heterogeneity, diffuse invasiveness, and the presence of a subpopulation of glioma cells with stem-like properties, herein termed brain tumor-initiating cells (BTIC; refs. 2, 3) , that have been shown to confer resistance to conventional therapies, such as radio-and chemotherapies (4) (5) (6) (7) (8) . Thus, to improve clinical outcomes, therapeutic agents should target both the infiltrative and tumor-initiating disease reservoirs.
Temozolomide is the current standard-of-care chemotherapy for glioblastoma. Although it improves the survival of patients, especially in the context of methylation of the O6-methylguanine DNA methyltransferase (MGMT) locus (9) , the survival benefit remains unsatisfactory and temozolomide resistance is common in the clinic (6, 10) . To improve the survival of glioblastoma patients, new therapeutic strategies including combination-based therapies are desperately needed. We have been investigating the treatments that are adjunctive to current standard-of-care and enhance the cytotoxicity of temozolomide using BTICs established from newly diagnosed and recurrent glioblastoma patients (2, 3, (11) (12) (13) as the screening platform. These cells retain cardinal features of stem cells including the ability to self-renew and differentiate into multiple neural cell lineages (2, 3) . They also have signature characteristics of transformed cells such as growth factor independence, tumorigenicity, and a spectrum of molecular genetic alterations known to occur in glioblastoma (e.g., p53, PTEN, IDH1, EGFR; refs. 2, 3, 13) . These highly tumorigenic cells form tumors in vivo that look and behave like glioblastoma including infiltration of the cerebral cortex and spreading along the subependyma and corpus callosum (3) . Using a highthroughput in vitro drug screen with two chemical libraries (NIH; ToolKit) we identified three candidate compounds, clioquinol, montelukast, and disulfiram for initial preclinical assessment. We found that DSF, an off-patent drug (FDA-approved) that crosses the blood brain barrier (BBB), had low nanomolar efficacy against patient-derived BTICs (including the highly infiltrative disease reservoir) when combined with copper gluconate and thus warranted further investigation.
Recently, several independent groups, including this study, have identified DSF through high-throughput screens as a potential therapeutic for the treatment of various cancers including glioblastoma (14) (15) (16) (17) (18) (19) . As DSF has been used clinically for over 60 years to treat alcoholism, its pharmacokinetics has been extensively studied and shown to have an excellent safety record at FDArecommended doses (20, 21) . DSF is available, inexpensive, safe, and overall well-tolerated making it an attractive candidate for "repurposing" in the context of glioblastoma. Although the anticancer mechanisms of DSF are still not well-understood (22) , published data indicate that the cytotoxicity of DSF is enhanced in the presence of copper (14, 15, 23) . DSF chelates bivalent metals such as copper (Cu) and zinc (Zn) to form DSF metal complexes that inhibit proteasome activity and block the degradation of IkB and NFkB nuclear translocation (24) (25) (26) . In the clinical situation, DSF combined with zinc gluconate has resulted in remission in a melanoma patient with liver metastasis (27) . The importance, however, of a bivalent metal such as copper for DSF's mechanistic action in the context of glioma, and specifically against the BTIC population, has not been examined.
In this study, we evaluated the use of DSF as a potential therapeutic drug for glioblastoma using a combination of in vitro and in vivo preclinical models. We demonstrate that in addition to being a potent proteasome inhibitor, DSF when chelated with copper downregulates the expression of a number of genes involved in DNA repair pathways. Consistent with this observation, we found that DSF-Cu enhanced the DNA-damaging effects of temozolomide, BCNU, and radiation (IR) in vitro and in combination with temozolomide prolonged survival in newly diagnosed, recurrent, and temozolomide resistant intracranial patient-derived BTIC models in vivo. Our observations suggest that as a single agent, DSF-Cu has limited in vivo efficacy; however, when given in the context of a DNA alkylating agent (temozolomide or BCNU) and/or DNA-damaging agent (IR), DSF-Cu has the potential to be repurposed for the treatment of patients with highly infiltrative glioma.
Materials and Methods

BTIC lines, tissue culture, and reagents
Surgical samples from patients with newly diagnosed and recurrent glioblastoma were obtained from the Tumor Tissue Bank within the Arnie Charbonneau Cancer Institute (Calgary, Alberta, Canada), transported to the BTIC Core Facility (Calgary, Alberta, Canada) and established as described previously (2, 3, 13) . All established cell lines used within this study were validated for identity by short tandem repeat analysis performed by Calgary Laboratory Services (CLS) after each thaw and for each experiment that involved intracranial xenografts. This study has Institutional review board approval under the "Brain Tumor and Related Tissue Bank protocol-V2" and approved by Foothills Hospital and the Conjoint Health Research Ethics Board.
Stable BTIC lines expressing enhanced firefly luciferase (effLuc) and eGFP were generated using a self-inactivating lentiviral vector system as described previously (28, 29) . BT73R and BT206R are temozolomide-resistant BTIC lines generated from parental BT73 and BT206. Briefly, BT73-and BT206expressing effLuc/eGFP were implanted into the brain of CB17 SCID mice (Charles River Laboratory) and two weeks after implantation, animals were treated with a temozolomide regime of 50 mg/kg/day (one cycle) followed by 5 cycles of 10 mg/kg/day (cycle ¼ 5 days on, 2 days off). Animals were monitored for recurrence at which time tumors were removed, dissociated, cultured under neurosphere conditions, and reimplanted into animals. Two weeks after the appearance of a recurrent tumor, animals were treated with a temozolomide regime of 50 mg/kg/day (one cycle) followed by 30 mg/kg/day (two cycles). Upon recurrence, tumor tissue was dissociated and cultured in neurosphere media. The derived temozolomide -resistant lines were termed BT73R and BT206R.
NIH clinical drug collection consists of 446 small-molecule compounds that have a history of use in human clinical trials. The library was purchased from Evotec Inc. The ToolKit library was provided by the Ontario Institute for Cancer Research (Toronto, Canada) and included 160 compounds. Disulfiram was purchased from AKT laboratories, montelukast was purchased from Gibco Life Technologies, copper (II) gluconate, clioquinol, and
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The following antibodies were used for Western blot analysis and IHC: mAbs against human nestin (R&D Systems, cat# MAB1259), human nucleolin (4E2, Abcam; cat# ab13541); phospho-histone H2AX (Ser139, clone JBW301; Millipore cat# 05-636); MGMT (Novus Biologicals, cat# NB100-168); b-actin (clone C4, EMD Millipore; cat# MAB1501); and polyclonal antibodies against MGMT (NEB, cat# 2739); PARP (Cell Signaling Technology, cat# 9542); Phosph-Ser 345 Chk1 (Cell Signaling Technology, cat# 2341), and Chk1 (Cell Signaling Technology, cat# 2360).
High-throughput screening and secondary validation
High-throughput screening was performed at the SMART Facility of the Lunenfeld-Tanenbaum Research Institute (Toronto, Canada), as described previously (30, 31) . Drug "hits" were defined as compounds that caused a signal decrease of at least 75% at a screening dose of 1 mmol/L as compared with controls. Compounds that exhibited greater than 50% but lower than 74% cytotoxicity were considered "intermediate potency hits." Secondary validation was performed on a subset of BTICs using 8-point, 3-fold serial dilutions of compounds.
For DSF viability assessment by AlamarBlue, cells were treated as indicated at the concentrations delineated in the text at 24 to 72 hours with the exception of temozolomide where viability was assessed on day 10. Five replicates per treatment were assessed and each experiment was repeated at least twice.
Self-renewal assay
BTIC self-renewal (secondary sphere-forming) assays were performed under neural stem cell conditions as described previously (3, 32) . Spheres were dissociated and viable cells were counted. Ten or 100 cells were then placed into 96-well plates and cultured for an additional 7 days, and secondary sphere formation was counted. Spheres >30 mm were counted and photographed using a Zeiss Axiovert 200M inverted fluorescent microscope and Axio-Cam MRc camera.
Apoptosis assay
Apoptotic status was determined by FITC-conjugated Annexin-V/PI assay kit (Roche) using flow cytometry following the manufacturer's instructions at 24 and 48 hours. Cells stained with Annexin V only were classified as cells undergoing early apoptosis and the Annexin V and PI double-stained cells were classified as cells in late apoptosis or necrosis. Whole brain sections were assessed for apoptosis using terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) to detect DNA fragmentation using InSitu Cell Death Detection Kit, Fluorescein (Roche Life Science, cat# 11684795910) following manufacturer's protocol. Sections costained for DNA damage were subsequently incubated with anti-phospho-histone H2AX (Ser139, clone JBW301) and secondary Alexa Fluor 488-conjugated goat anti-mouse lgG and counterstained with 4 0 ,6-diamidino-2-phenylindole (DAPI; blue) to visualize the nuclei.
Western blot analysis
Cells were harvested following treatment, washed with PBS, and sonicated in 50 nmol/L Tris-HCI (pH 8.0) containing 1% glycerol, 1 mmol/L EDTA, 0.5 mmol/L phenylmethylsulfonylfluoride, and 2 mmol/L benzamidine. Equal protein amounts were subjected to SDS-PAGE, transferred to nitrocellulose, and Western blot analysis was performed as described previously (33, 34) using the appropriate primary and secondary antibodies.
Chymotrypsin-like (26S) activity proteasome assay
Chymotrypsin-like (CT) activity (26S activity) was measured using the CT-like proteasome-Glo assay (Promega) at 24 or 72 hours following treatment. Luminescence was measured using a luminometer (SpectraMax) and activity was reported as the mean percent activity compared with control.
For in vivo analysis of 26S proteasome activity, animals bearing BTIC intracranial tumors were treated with vehicle (Oral Plus), DSF, or DSF-Cu for 5 and 10 days; following treatment, animals were sacrificed, tumor tissue was collected, and 26S proteasome activity was assessed using the proteasome activity assay (ab107921; Abcam).
GammaCell irradiation
Cells grown on laminin (L202; Sigma) coated coverslips or plated in 6-cm plates were either untreated or treated with DSF-Cu (50 nmol/L DSF; 200 nmol/L Cu) 12 hours before irradiation treatment. Following the 12-hour pretreatment, cells were either untreated, treated with [(10 mg/mL, (51.5 mmol/L) TMZ] or irradiated using a GammaCell 1000 Elite Tissue Irradiator (dose rate 2.94 Gy/minute, 41 seconds to deliver a dose of 2 Gy to cells on coverslips, and 102 seconds to deliver a dose of 5 Gy to cells in 6-cm plates) followed by recovery at 37 C for the indicated time points (hours).
Immunofluorescence and assessment of DNA damage
Cells grown on 8-well chamber slides or laminin (L202; Sigma) coated coverslips were fixed in 4% paraformaldehyde and permeabilized with addition of 0.1% Triton-X100 prior to immunostaining. Primary mouse monoclonal anti-phospho-histone H2AX (Ser139, clone JBW301) and secondary Alexa Fluor 488conjugated goat anti-mouse lgG were sequentially applied. For whole brain tissue sections, paraffin-embedded tissues were deparaffinized with xylene, rehydrated through an ethanol gradient, and treated as described previously (33) to staining with anti-phospho-histone H2AX. Nuclei were counterstained with 2 mg/mL of DAPI and chambers were removed and coverslips were mounted onto the glass slides. DNA damage was visualized by immunofluorescence microscopy using the InCell 6000 (GE Healthcare Life Sciences) or a Zeiss platform microscope (Axio Observer.ZI; Carl Zeiss), with a Plan Apochromat 20Â/0.8 NA, an EC Plan Neofluar 40Â/0.75 NA, or a Plan Apochromat 63Â/1.4 NA (oil immersion) objective and camera (AxioCam MRm Rev.3; Carl Zeiss). Acquisition and analysis software used was Zen Pro (Carl Zeiss). DNA damage was assessed by manual foci counting.
Microarray
RNA was extracted from 500,000 cells treated for 12 hours (as indicated) using mirVana miRNA Isolation Kit (Ambion) according to the manufacturer's protocol. Total RNA was purified with RNeasy Plus Micro Kit (Qiagen) and RNA integrity number (RIN) was measured using the Agilent RNA 6000 NanoChip on 2100 Bioanalyzer (Agilent Technologies). Quantity was measured using NanoDrop 1000 (NanoDrop Technologies, Inc) and 100 ng of RNA with a RIN higher than 9 was labeled with 3 0 IVT Express Kit (Ambion) and hybridized to Affymetrix Gen-eChip Human PrimeView Arrays at 45 C for 16 hours. Arrays were stained using Affymetrix GeneChip Fluidics_450 following manufacturer's protocol and scanned using the Affymetrix GeneChip Scanner 3000 7G System. The raw datasets for array comparisons have been deposited in the Gene Expression Omnibus website (http://www.ncbi.nlm.nih.gov.geo/; accession number, GSE76146).
Microarray data analysis
Affymetrix GeneChip array data files were generated using GeneChip Command Console Software (AGCC) and statistical analysis was carried out using Partek Genomics Suite 6.0 (Partek Incorporated, USA). Of the 20,000 genes represented on the array, the fold change was calculated as compared with control. To categorize biologic functions related to gene expression altered by DSF-Cu treatment, fold-change files were uploaded into DAVID Bioinformatics Resources 6.7 (National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD).
In vivo experiments
Six-to 8-week-old female SCID mice (CB17) from Charles River Laboratory were used in this study. All protocols were reviewed and approved by the Animal Care Committee of the independent laboratory and the University of Calgary (Calgary, Alberta, Canada). All animal work procedures were in accordance with the Guide to the Care and Use of Experimental Animals published by the Canadian Council on Animal Care and the Guide for the Care and Use of Laboratory Animals issued by NIH (Bethesda, MD).
Characterization of BTICs in vivo
Patient-derived BTICs from newly diagnosed (BT73, BT108, BT126, BT127, BT134, BT164) and recurrent (BT119, BT143, BT147) tumors were implanted into the brain of mice as described previously (3, 32, 34) . Mice were monitored weekly and tumor growth was assessed using the IVIS-200 Optical in vivo imaging system, MRI, or by IHC at designated timepoints. Immunohistochemical assessment was performed after formalin fixation, paraffin embedding, and sectioning of the brains. All sections were stained with hematoxylin and eosin (Eosin, Anatech Ltd, cat# 832) and IHC was performed using human-specific mAbs against nestin (1/200), human nucleolin (R&D Systems; 1:500), g-H2AX (1/100) at 4 C overnight and detected using DAKO Envision and System-HRP Kit (cat# K4007). Slides were counterstained with hematoxylin (Sigma, cat# GHS232-1L), mounted, and imaged using a Zeiss inverted microscope (Axiovert 200M) and camera (AxioCam MRc).
In vivo efficacy studies
In vivo efficacy studies were determined by stereotactically implanting 1 Â 10 5 BTIC cells into the right striatum of SCID mice (Charles River Laboratory; refs. 3, 32) . Tumors were allowed to grow for 7 days at which time animals were treated as follows: clioquinol was administered daily via intraperitoneally injection to animals bearing intracranial BT147 tumors at a concentration of 15 mg/kg clioquinol in 20% intralipid once per day or twice per day for 4 cycles (5 days on, 2 days off). Montelukast was administered daily via intraperitoneal injection to animals bearing intracranial BT147 tumors at a concentration of 25 mg/kg montelukast in H 2 O once per day for 3 cycles (5 days on, 2 days off). DSF-Cu and/or temozolomide, was administered to mice with intracranial patient-derived BTIC tumors (BT73, BT73R, BT134, and BT147) by oral gavage. Treatment groups included Oral Plus (vehicle control); DSF-Cu [DSF, 100 mg/kg/daily, copper (Cu) 2 mg/kg/daily]; temozolomide (50 mg/kg/mouse/daily), or temozolomide plus DSF-Cu via gavage starting 7 days after tumor implantation. DSF and Cu were delivered as separate formulations via gavage. Animals were treated for 3 cycles with each cycle consisting of 5 days of treatment followed by two nontreatment days. All treatment groups consisted of 8-12 animals as indicated. Animals were monitored and imaged weekly for tumor burden by bioluminescence using the IVIS-200 Optical in vivo imaging system, by MRI using 9.4 T NMR instrument in the Experimental Imaging Center (University of Calgary, Calgary, Alberta, Canada) or by IHC of formalin-fixed, paraffin-embedded whole brain sections. Animals assessed for survival were monitored until they lost !20% of body weight or had trouble ambulating, feeding, or grooming, or until the experiment was terminated.
Statistical analysis
Statistical Analysis Software (SAS Institute, Inc.) and GraphPad Prism (version 4; GraphPad Software, Inc.) were used for statistical analyses. Survival curves were generated using the Kaplan-Meier method. The log-rank test was used to compare the distributions of survival times. A P value of less than 0.05 was considered statistically significant. Experimental data was collected from multiple experiments and reported as the treatment mean AE SE. Significance was calculated using the Student t test or oneway ANOVA where Ã , P < 0.05 and ÃÃ , P < 0.01 or as indicated.
Results
Screening BTICs for cytotoxicity to clinically approved drugs
To screen for drugs that could prevent the proliferation and survival of BTICs, we performed a primary screen with the NIH clinical drug library (Evotec, Inc.) that contains 446 compounds that have been used in human clinical trials, and a ToolKit library (Ontario Institute for Cancer Research, Toronto, Ontario, Canada) containing 160 compounds against 13 independent genetically distinct patient-derived BTIC lines (BT-12, 25, 50, 53, 67, 68, 73, 84, 89, 108, 119, 124, 147) cultured using standard neurosphere conditions (refs. 3, 13, 32, 35; described in Fig. 1A and ref. 30 ). On the basis of established genetic alterations observed in glioblastoma, the panel of BTICs screened was chosen to encompass the molecular heterogeneity of the disease as assessed by mutational status of EGFR, PTEN, p53, and MGMT promoter methylation status and were derived from both newly diagnosed and recurrent tumors (summarized in Supplementary Table S1 ; refs. 2, 3, 13). Compounds were identified that exhibited more that 50% growth inhibition at 1 mmol/L in all BTIC cultures using AlamarBlue reduction as we have previously described (30, 31) . Compounds that exhibited greater than 50% but lower than 74% cytotoxicity were considered "intermediate potency hits" and indicated in yellow while compounds demonstrating greater than 75% growth inhibition were defined as "strong hits" and indicated in green ( Fig. 1B and C) . To validate the compounds identified from the primary screens, a secondary independent screen with a random selection of BTICs was performed using 8-point serial dilutions and the IC 50 for each compound was calculated. On the basis of the relatively large number of hits (30 drugs), compounds were further prioritized on the basis of showing efficacy on most or all primary-BTIC lines and on their ability to cross the blood-brain barrier (BBB). Many compounds from the list, such as idarubicin, doxorubicin, epirubicin, clofazimine, dactinomycin, bortezomib, and ouabain were reported to not cross the BBB and were therefore not pursued further. To prioritize among the remaining compounds, we used six criteria (summarized in Supplementary Table  S2 ): (i) efficacy on BTICs in vitro; (ii) potency in vitro (nanomolar to low micromolar); (iii) BBB penetration and brain accumulation; (iv) clinical status; (v) toxicity to normal cells; and (vi) novelty. From the prioritized list, the top candidates were assessed in a secondary screen performed on a subpanel of patient-derived BTICs using 8-point serial dilutions (Supplementary Figs. S1A, S2B, and S3). From these candidate compounds, we chose montelukast, a leukotriene receptor antagonist used for the treatment of acute asthma (36, 37) , clioquinol, a hydroxyquinoline that has been used as an antifungal and antiprotozoal drug (38) , and disulfiram, an off-patent drug previously used to treat alcoholism (21, 39) for further assessment. While in vitro studies were validated for clioquinol ( Supplementary Fig. S1A and ToolKit (C) as described previously (30) . A, schematic outlines the high-throughput screen. BTICs were dissociated into single cells and seeded at 5,000 cells/well in 100-mL medium in 96-well microplates. Compounds were dissolved in DMSO, realiquotted in daughter plates as 1 mmol/L solutions, and added using a pin tool to achieve a final concentration of 1 mmol/L. Drug effects were compared with cells optimally proliferating in 0.1% DMSO alone, while wells filled with media served as background. AlamarBlue (10 mL) was added after 72 hours, and fluorescence intensity measured after 6 hours on a PHERAstar microplate reader, equipped with a l540 excitation/ l590 emission filter. B and C, tables show compounds from NIH (B) and Toolkit (C) libraries that exhibited greater than 50% (yellow) or 75% (green) growth inhibition at 1 mmol/L in all 13 BTIC cultures as compared with controls. (Continued on the following page.) cross the BBB ( Supplementary Fig. S1B ), preclinical assessment was halted on the basis of toxicities we observed when administered to mice, and the inability to demonstrate improved survival in a patient-derived intracranial model (BT147; Supplementary  Fig. S1C -S1E). Similarly, while montelukast ( Supplementary Fig.  S2 ) was validated in vitro ( Supplementary Fig. S2B and S2D), this compound also showed signs of toxicity as a single agent in vivo and failed to demonstrate survival benefit ( Supplementary Fig.  S2E and S2F). We therefore focused upon further assessment of disulfiram. While the evaluation of DSF is certainly not unique in the cancer setting (14-16, 19, 25, 27, 40) , including studies in glioma (17, 41, 42) , in vivo preclinical assessment for glioblastoma has not been performed. Thus, the independent validation of activity against the patient-derived glioma cells, DSF's low nanomolar efficacy on these cells, BBB penetration, and its extensive multi-decade clinical use with very little evidence of adverse drug reactions made it desirable to pursue in a rigorous preclinical assessment regime. DSF requires copper for effective killing and inhibition of self-renewal of genetically distinct patient-derived BTICs As described above, DSF was found to be highly effective at killing a wide range of patient-derived BTICs, an observation consistent with recent in vitro reports using human glioma cell lines (17, 18, 41, 43) ; however, in vivo testing has not been performed and discrepancies with respect to the IC 50 and the requirement of copper for its therapeutic effects exist (17, 18) . We found that while some patient-derived BTICs were sensitive to the treatment with DSF alone (Fig. 1E ), many of the BTICs including BTICs resistant to treatment with temozolomide ( Supplementary Fig. S4; ref. 11 ) were resistant (Fig. 1D) . We confirmed that all BTICs tested were capable of forming tumors in vivo ( Fig. 1D and E) and found that their sensitivity or resistance to DSF alone in vitro was independent of mutational status (p53, EGFR, PTEN), MGMT methylation status, or previous treatment (newly diagnosed vs. recurrent; Supplementary  Table S1 ; refs. 2, 3, 13) . Moreover, we found that the addition of copper gluconate (Cu, 200 nmol/L) increased sensitivity and cell killing including BTICs resistant to DSF alone ( Fig. 2A and Supplementary Fig. S5A and S5B; ÃÃ , P < 0.001 comparing DSF-Cu with DSF or Cu alone) and significantly inhibited the selfrenewal ability ( Fig. 2B ; ÃÃ , P < 0.001 comparing DSF-Cu with DSF or Cu alone).
DSF-Cu augments the cytotoxic effects of temozolomide and enhances apoptosis
We next determined whether combination therapy with DSF-Cu and standard-of-care temozolomide could promote or enhance efficacy of DSF-Cu in vitro. We found that low dose DSF-Cu significantly increased temozolomide cell killing in vitro ( Fig. 2C and Supplementary Fig. S6A and S6B; ÃÃ , P < 0.001 comparing temozolomide plus DSF-Cu with temozolomide or DSF-Cu alone) and importantly overcame the temozolomide resistance observed in some of the BTIC cell lines including temozolomide-resistant BTIC variants (BT73R and BT206R) established from newly diagnosed patient-derived BT73 and BT206 ( Fig. 2E-H) . Moreover, this enhancement of BTIC susceptibility in the presence of temozolomide together with DSF-Cu does not rely on the status of MGMT as inhibition of MGMT by O6-benzylguanine (43, 44) did not inhibit the ability of DSF-Cu/ temozolomide to decrease cell viability ( Supplementary Fig. S7 ). This is consistent with, DSF-Cu/temozolomide significantly inhibiting cell viability of temozolomide-resistant BTIC variants that either express (BT73R) or do not express (BT206R) MGMT ( Fig.  2E) , further supporting the notion that DSF-Cu/temozolomide sensitivity can be independent of MGMT status ( Supplementary  Fig. S7 ). In addition, DSF-Cu when combined with clinically relevant doses of temozolomide induced more apoptosis than either compound alone as assessed by FACS analysis and PARP cleavage ( Fig. 2D and Supplementary Fig. S6D-S6F ). This combination benefit is of direct clinical interest given the extensive use of temozolomide in the clinic and the associated problems with temozolomide-related resistance and treatment failure.
DSF inhibits both the proteasome and reduces DNA repair capabilities
DSF has been reported to have several biologic activities including its well-characterized activity as an aldehyde dehydrogenase (ALDH) inhibitor for the treatment of alcoholism, its ability to be an effective proteasome inhibitor (26S), and recently, its ability to inhibit the activity of MGMT (43) . Moreover, there is growing literature to suggest that the anticancer properties of DSF do not rely solely on its ability to inhibit ALDH (45), a mechanism that does not require Cu. As we show a requirement for Cu for effective killing of all patient-derived BTICs, we investigated alternative mechanism(s)-of-action. We first investigated the requirement for Cu to inhibit the 26S activity of the proteasome, a mechanism suggested for DSF in other cancers (26) . Using both newly diagnosed and recurrent patient-derived BTICs, we found that the addition of Cu was required for DSF to inhibit the 26S proteasome activity (Fig. 3A and B and Supplementary  Fig. S8 ). Moreover, when DSF-Cu was directly compared with the clinically approved proteasome inhibitor bortezomib, we found that bortezomib was not able to elicit the same robust cell death seen with DSF-Cu even at concentrations that completely inhibit the proteasome (Fig. 3A and B ). In addition, when BTICs were treated with very low concentrations of DSF-Cu, concentrations where proteasome inhibition was not maximal, DSF-Cu was still able to effectively kill the BTICs (Fig. 3A and B and Supplementary Fig. S8 ). Thus, inhibition of the proteasome may be responsible for some but not all of the cytotoxicity of DSF-Cu in BTICs.
To identify other mechanisms of action specific to the DSF-Cu complex, we performed global gene expression analysis before and after treatment with DSF, Cu, or DSF-Cu. As expected, when BTICs were treated with Cu alone, we observed the induction of a number of genes in the metallothionein family, which comprise Cu-binding proteins that protect against oxidative stress. In the DSF-Cu-treated cells, we also observed a number of very specific changes in gene expression including the downregulation of a large number of genes, many of which have been implicated in DNA damage and repair pathways both in vitro and in vivo ( Fig. 3C and D; Supplementary Table S3 ). On the basis of these data, we assessed whether DSF-Cu was able to enhance the DNA damage induced by temozolomide. We found that cells treated with the combination therapy of DSF-Cu and temozolomide had increased DNA damage as assessed by immunostaining and Western blot analysis for g-H2AX ( Fig. 4A-D) . These data suggest that the DNA repair pathways were suppressed by DSF-Cu and provide a new mechanism of action to explain the ability of DSF-Cu to enhance the therapeutic effects of temozolomide. Moreover, we found that this augmentation of DNA damage was not limited to temozolomide and was also observed when cells were treated with IR ( Fig. 4C-F) where DSF-Cu was found to increase the accumulation of g-H2AX-positive foci and inhibit the DNA repair protein Chk1. In addition, assessment of a second independent DNA alkylating agent, Carmustine (BCNU), together with DSF-Cu resulted in increased efficacy ( Supplementary Fig.  S6C ) further supporting the idea that DSF-Cu is working at least in part by suppressing DNA repair pathways.
DSF-Cu combined with temozolomide significantly inhibited tumor growth and prolonged survival in patient-derived BTIC intracranial models
As the in vitro data indicated that DSF-Cu is cytotoxic in a wide range of patient-derived BTICs and had the ability to enhance the cytotoxic effects of temozolomide in vitro, we assessed the clinical applicability of this treatment regime in our well-defined preclinical in vivo models (2, 3, 13, 32) . For these studies, we chose genetically distinct patient-derived BTICs established from a newly diagnosed (BT134: P53WT, PTENWT, EGFR WT, MGMT unmethylated), recurrent (BT147: P53mut, PTEN À/À , EGFRVIII, MGMT unmethylated), and temozolomide-resistant (BT73R) tumors. These BTIC lines exhibited resistance to temozolomide even at high concentrations (10 mg/mL) in vitro ( Fig. 2E , Supplementary Figs. S4 and S5), thus allowing for the assessment of the DSF-Cu-temozolomide combination therapy in vivo. Using intracranial murine xenograft models that had visible tumors by day 7 as assessed by the IVIS-200 Optical in vivo imaging system, we randomly assigned animals to the following groups: (i) vehicle control, (ii) temozolomide alone, (iii) DSF-Cu alone; or (iv) temozolomide plus DSF-Cu. Temozolomide and DSF-Cu were given as daily oral administration for 3 cycles (5 days on, 2 days off) at a dose of 30 or 50 mg/kg for temozolomide, 100 mg/kg for DSF, and 2 mg/kg copper (II) gluconate. Animals were monitored every other day and tumor growth was measured at weekly intervals using the IVIS-200 system (total flux emission photons/second). A decrease in tumor burden (signal intensity) was observed in animals treated with the combination therapy (temozolomide plus DSF-Cu). In contrast, no decrease in signal intensity was observed in animals treated with DSF-Cu alone (Fig. 5A and B and Supplementary Fig. S9A and S9B ). Quantitative analysis of tumor burden ( Fig. 5A and B ) demonstrated a consistently smaller tumor burden in the animals treated with DSF-Cu-temozolomide as compared with the continuous increase in tumor burden observed in control animals, DSF-Cu, or temozolomide-treated animals. To confirm the imaging data with respect to an independent measure of tumor burden, 2-3 animals/group were sacrificed 3 weeks following treatment, brains were fixed, paraffin-embedded, and assessed histologically for tumor burden as shown in Supplementary Fig. S10 (top two panels) . In addition, whole brain sections were assessed for apoptosis using TUNEL (bottom panel). These data confirmed the in vitro results where the combination-based therapy resulted in increased apoptosis as compared with the single agents or control animals (Supplementary Fig. S6D-S6F ). Importantly, we demonstrated that while DSF-Cu did not prolong overall survival, and temozolomide had a modest impact in overall survival, the combination of the two drugs had a marked increase in overall survival on newly diagnosed, recurrent, and temozolomide-resistant BTIC intracranial models [ Fig. 5A-C ; log-rank test, P < 0.0001 (Fig. 5A) ; P ¼ 0.0006 (Fig. 5B) ; P ¼ 0.0030 (Fig. 5C)] .
To assess the DSF-Cu-temozolomide combination-based therapy in a more clinically relevant formulation, experiments were performed using clinical grade DSF and a copper supplement that can be purchased in many health food stores (copper bisglycinate). Using in vitro assays, the combination of copper bisglycinate with DSF was found to be superior to other copper supplements (Centrum Forte; Copper D-gluconate) as assessed by proteasome inhibition (Supplementary Fig. S8C ). Most importantly, the clinical grade DSF with copper bisglycinate in combination with temozolomide significantly prolonged survival in animals bearing BT147 intracranial tumors ( Supplementary Fig. S9D ). Interestingly, using this combination, DSF with copper bisglycinate alone was able to prolong survival, a result that may be consistent with the improved inhibitory activity in vitro ( Supplementary Fig.  S8C ). As a surrogate of therapeutic response in vivo, we assessed the level of 26S proteasome inhibition in tumor-bearing animals (BT147 and BT73) 5 and 10 days following treatment and found that the ability for DSF to inhibit the 26S activity of the proteasome in vivo was enhanced in the presence of the copper supplement, copper bisglycinate, after 10 days of treatment (Fig. 6A) .
One hallmark of proteasome inhibition is the induction of an ER stress response; we therefore treated BTICs with DSF-Cu or the clinically approved proteasome inhibitor bortezomib and also assessed for the expression of the ER stress-responsive transcription factor C/EBP homologous protein (CHOP) by Western blot analysis. Treatment with DSF-Cu or bortezomib for 24 hours both resulted in the increased expression of CHOP (Fig. 6B) . In addition, and consistent with in vitro data, IHC for g-H2AX in whole brain sections from BT147-bearing animals confirmed in vivo the ability of DSF-Cu to enhance the DNA damage induced by temozolomide ( Fig. 6C-E ). To rule out that the increase in g-H2AX was not the consequence of an increase in apoptosis, sections were costained for TUNEL and g-H2AX (Fig. 6E ). No significant overlap was observed between nuclear g-H2AX and TUNEL suggesting that the appearance of g-H2AX-positive foci is a direct consequence of increased DNA damage and not the result of cells undergoing apoptosis. Collectively, these data show that both g-H2AX and CHOP increase in response to treatment with DSF-Cu.
Discussion
Despite a deeper molecular understanding of the genetic alterations in human glioma the attempts to translate this information into the clinic through molecularly targeted agents has remained a considerable challenge with very limited success. There are several barriers to effective treatment including tumor heterogeneity, infiltrative nature of the disease, and the lack of many drugs that effectively cross the BBB. We would also argue that many of the cell-based models used for drug screening and assessment may not be predictive and do not account for the complexities of the disease. In recent years, there has been considerable attention to the presence of a stem-like population of glioma cells (4, 5, 46, Tumors were allowed to form for 7 days at which time animals were treated with (i) Oral Plus (control) or (ii) 30 mg/kg temozolomide once per day for 3 cycles (5 days on, 2 days off). Animals were monitored daily. Graphs show Kaplan-Meier survival analysis. N ¼ 5-6 animals/group; P < 0.0001 for temozolomide as compared with control for BT73 and BT206 while the resistant variants had P values equal to 0.09058 (BT73R) and 0.3687 (BT206R) as compared with the control treatment (log-rank test). Arrows indicate the start of temozolomide treatment on day 7. (BT73 and BT134) fixed and stained for g-H2AX to visualize DNA damage and counterstained with DAPI (blue) to visualize the nuclei. Images were taken at 40Â magnification. B, Western blot analysis of g-H2AX expression confirms the increase in g-H2AX in BT73 (left) and BT134 (right) in response to DSF-Cu. b-Actin was used as a loading control. C-E, BT134 and BT147 were treated with 2 and 5 Gy IR, or 10 mg/mL (51.5 mmol/L) temozolomide in the absence or presence of DSF-Cu (12-hour pretreatment with 50 nmol/L DSF/ 200 nmol/L Cu) and assessed for DNA damage at 1, 6, 12, and 24 hours. C, shown are representative images of cells plated on laminin-coated coverslips, treated with 2 Gy IR or temozolomide in the absence or presence of DSF-Cu. Cells were fixed at times indicated and stained for g-H2AX to visualize DNA damage using fluorescent microscopy. Images were taken at 60Â magnification. D, bar graph shows quantitation of the average number of g-H2AX-positive foci/cell in BT147. Asterisks ( ÃÃ ) P < 0.001 and P ¼ 0.01 for IR plus DSF-Cu compared with IR alone; P < 0.0001 for temozolomide compared with control at 6, 12, and 24 hours (Student t test). E, graph shows percentage cell viability of BT134 and BT147 following treatment with saline (control), copper alone (200 nmol/L), DSF (100 nmol/L), or DSF-Cu in the presence or absence of IR (5 Gy). ÃÃ , P ¼ 0.0001 for BT134 IR plus DSF-Cu compared with IR or DSF-Cu alone. F, Western blot analysis using antibodies to phos-Chk1, Chk1, PARP, and g-H2AX on cell lysates from BT134 and BT147 untreated (control) or treated with 5 Gy IR in the absence or presence of DSF-Cu (12-hour pretreatment with 100 nmol/L DSF/ 200 nmol/L Cu). Hela cells were used as a positive control for IR and b-Actin was used as a loading control.
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Tumor size (Log10, photons/sec) 1.00E+05 Figure 5 . Temozolomide (TMZ) combined with DSF-Cu inhibits tumor growth and improves survival in patient-derived BTIC intracranial models in vivo. Animals bearing intracranial BT134 (A) or BT147 (B) effLuc/eGFP tumors were treated with (i) vehicle control, (ii) temozolomide alone, iii) DSF-Cu alone or iv) temozolomide plus DSF-Cu. Temozolomide and DSF-Cu were given as daily oral administration for 3 cycles (5 days on, 2 days off) at a dose of 50 mg/kg for temozolomide, 100 mg/kg for DSF, and 2 mg/kg cooper (II) gluconate. Animals were monitored every other day and assessed for survival. A and B, tumor growth was measured at weekly intervals using the IVIS-200 Optical in vivo imaging system. Graphs (left) show quantitative assessment of tumor burden as analyzed by the IVIS-200 system (Log10, total flux emission photons/second); Animals were monitored for survival (right). Graphs show Kaplan-Meier assessment. P < 0.0001 (BT134) and P ¼ 0.0006 (BT147) for temozolomide/DSF-Cu as compared with temozolomide alone (log-rank test). N represents the number of animals per group. Arrows indicate the start of treatment. C, in vivo efficacy of BT73R following treatment with clinical grade DSF-Cu (100 mg/kg) and copper bisglycinate (2 mg/kg), temozolomide (30 mg/kg) or temozolomide plus DSF-Cu was determined as described above. N ¼ 5-7 animals/group; P ¼ 0.003 for temozolomide/DSF-Cu as compared with temozolomide alone (log-rank test). Arrow indicates initiation of drug administration. D and E, shown is Western blot analysis of MGMT expression in BT73R following treatment with DSF alone or in combination in vitro (D) or in vivo (BT73R and BT147; E). b-Actin or human nucleolin (to detect the in vivo presence of human tumor cells) were used as loading controls. Binding of the secondary antibody to in vivo mouse (Ms) IgG is indicated. 47), termed as BTICs, that have been shown to re-populate a tumor (recurrence) and confer resistance to conventional therapies, including temozolomide and radiation (4, 6, 11, 13, 48) . In this study, we focused on this population of cells as a model and platform to develop new therapeutic strategies to improve the therapeutic efficacy of standard of care (temozolomide) in the adjuvant setting.
Our focus has been on exploring already marketed (clinically approved) drugs that demonstrate therapeutic potential against the stem-like glioma population. Using a high-throughput in vitro drug screen, we found that disulfiram, an off-patent drug previ-ously used to treat alcoholism, in the presence of copper gluconate, or copper bisglycinate, had low nanomolar efficacy against patient-derived BTICs, including the highly infiltrative disease reservoir, in vitro. While we found that some glioma lines did not require additional supplemental copper for effective killing, it is clear that in the presence of copper, sensitivity is greatly enhanced, and more importantly, temozolomide resistance can be overcome. In fact, we demonstrate that DSF-Cu can sensitize a completely temozolomide-resistant line to temozolomide. While the exact mechanisms of action for DSF versus DSF-Cu remain unknown we have provided compelling data to suggest that when Assessment of DSF efficacy using clinically relevant markers. A, snap frozen tumor tissue from animals bearing BT73 or BT147 following treatment with DSF (100 mg/kg) or DSF-Cu (100 mg/kg plus 2 mg/kg Cu) for 5 and 10 days were assessed for 26S proteasome chymotrypsin-like activity. Graph shows the percentage of proteasome activity in vivo as compared with tumor tissue from control animals treated with Oral Plus. Ã , P < 0.05; ÃÃ , P < 0.001 respectively. B, BT73 and BT147 cells treated with DSF (100 nmol/L) or DSF-Cu (100 nmol/L plus 200 nmol/L Cu) for 24 hours were lysed and proteins were resolved on 12% SDS-PAGE gels. Western blot analysis for the ER stress protein CHOP was performed. The clinically approved proteasome inhibitor bortezomib (BZB; 50 nmol/L) was used for comparison. b-Actin was used as a loading control. C-E, formalin-fixed, paraffinembedded tissue from animals bearing BT147 following treatment with temozolomide (TMZ; 50 mg/kg), DSF-Cu (100 mg/kg DSF plus 2 mg/kg Cu), or a combination of DSF-Cu/ temozolomide for 5 days were stained with anti-human nucleolin (brown; C) to detect the presence of tumor cells; anti-g-H2AX antibody to detect DNA damage (brown; D), or costained for the presence of apoptosis by TUNEL (green; E), DNA damage by antig-H2AX (red), and DAPI (blue) to visualize the cell nuclei. Sections were counterstained with hematoxylin and images were taken at 60Â magnification (C and D) or visualized by fluorescence microscopy (E) at 40Â magnification. combined with copper, DSF is a potent inhibitor of the 26S proteasome as well as an enhancer of DNA-damaging agents due to suppression of DNA repair pathways. Of note, a recent study showed that DSF directly inhibited the expression of MGMT, an enzyme that removes O6 akyl groups from guanine, a repair function in error-free DNA replication (43) . However, the reduction of MGMT occurred at concentrations of DSF significantly higher than the IC 50 of the BTICs. Targeting cancer stem cells (CSC) for better therapeutic outcomes is receiving considerable attention and as ALDH is being used as a biomarker of CSCs, it has been proposed that DSF may be a good therapeutic option (18, 49, 50) . However, our data suggest that DSF-Cu is essential for the increased cytotoxicity and ALDH inhibition alone is unlikely to account exclusively for its therapeutic effects in vitro and in vivo. Our study instead suggests a more global impact for DSF-Cu in affecting proteasome inhibition and DNA repair pathways, and supports the hypothesis that DSF-Cu acts as a multimodality agent in the setting of targeting glioblastoma.
On the basis of a number of features of DSF such as its ability to cross the BBB, low toxicity profile, and its affordability, we believe that DSF-Cu should be tested in glioma patients as an adjunctive treatment to standard of care. MGMT promoter methylation remains the strongest predictive marker for treatment outcome for patients with newly diagnosed glioblastoma (9, 51) . It is clear that patients with unmethylated MGMT require better treatment options as their therapeutic benefit to temozolomide is minimal. On the basis of our findings that DSF-Cu is able to enhance the therapeutic effects of temozolomide in both MGMT-positive and MGMT-negative BTICs both in vitro and in vivo (Figs. 2, 5 , and Supplementary Figs. S6 and S7) suggests that unmethylated glioma patients could benefit from the addition of DSF-Cu within their treatment regime. Clearly, the ability to enhance the therapeutic effects of temozolomide and/or BCNU would be advantageous but may come with some added side effects requiring assessment of the toxicity profile of DSF when combined with copper in a phase I study. In addition, we do not know if DSF-Cu targets and/or accumulates preferentially in the glioma cells in vivo, and if not, may result in unwanted side-effects in combination with temozolomide, although arguably we have never observed increased toxicity in our preclinical animal models. In addition, based on the results presented here, DSF-Cu may act to enhance the effects of other chemotherapeutic agents used in glioma such as Carmustine and thus warrant assessment of DSF-Cu in combination with other DNA-damaging agents including agents that have shown toxicity in the clinic, as combination with DSF-Cu may allow for a reduction in the dose of the chemotherapy with therapeutic benefit. The notion that DSF-Cu may allow one to lower the amount of temozolomide to gain therapeutic benefit may help reduce both associated toxicities and progression-related mutator phenotypes.
It would certainly be worth considering the use of DSF-Cu in the neoadjuvant and adjuvant setting both in newly diagnosed and recurrent patients as based on the newly described mechanism of action, namely inhibiting DNA repair, DSF-Cu may act as a radiation sensitizer at the time of radiotherapy. Moreover, we believe that our observations are not limited to repurposing DSF solely for glioma but could be used when combined with a copper supplement in a number of cancers for which resistance to DNA-damaging agents is commonly observed and in situations when targeting DNA repair coupled with proteasome inhibition demonstrates therapeutic benefit such as in multiple myeloma (52) .
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